The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2015

Filed:

Oct. 23, 2012
Applicant:

Glaxosmithkline Intellectual Property (No. 2) Limited, Brentford, Middlesex, GB;

Inventors:

Thomas Francis Hendrickson, Encinitas, CA (US);

Koc-Kan Ho, Holladay, UT (US);

Michael David Saunders, Sandy, UT (US);

Brian John Stevens, Salt Lake City, UT (US);

Krzysztof Swierczek, West Jordan, UT (US);

Kevin Bret Wright, Cottonwood Heights, UT (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 401/02 (2006.01); C07D 401/10 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.


Find Patent Forward Citations

Loading…